An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study) - Coombes, R.C.; Tat, T.; Miller, M.L.; Reise, J.A.; Mansi, J.L.; Hadjiminas, D.J.; Shousha, S.; Elsheikh, S.E.; Lam, E. W-F.; Horimoto, Y.; El-Bahrawy, M.; Aboagye, E.O.; et al. (Annals of oncology, 2013)
Keywords: Adult; Aged; Antineoplastic agents; Biological and medical sciences; biomarker; Biopsy; breast; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cell Proliferation - drug effects; ErbB Receptors - metabolism; Female; Forkhead Box Protein M1; Forkhead Box Protein O3; Forkhead Transcription Factors - metabolism; Gene Expression Regulation, Neoplastic - drug effects; Gynecology. Andrology. Obstetrics; HER-3; Humans; Ki-67 Antigen - metabolism; Ki67; Lapatinib; Mammary gland diseases; Medical sciences; Middle Aged; Oncogene Protein v-akt - metabolism; Pharmacology. Drug treatments; pre-surgical; Quinazolines - administration & dosage; Receptor, ErbB-2 - genetics; Receptor, ErbB-3 - metabolism; Receptors, Estrogen - metabolism; Tumors; pre-surgical; lapatinib; biomarker; HER-3; Ki67; breast; Antineoplastic agent; Breast disease; erbB2 Gene; Biological marker; Surgery; Lipopolysaccharide; Adult; Female; Mammary gland; Lapatinib; Woman; Protein-tyrosine kinase; Protooncogene; Human; Enzyme; Tyrosine kinase inhibitor; Transferases; Enzyme inhibitor; Breast cancer; Malignant tumor; Human Epidermal growth factor Receptor 2; Human Epidermal growth factor Receptor 3; Mammary gland diseases; Treatment; C-Onc gene; Ki67 antigen; Breast; Early; Cancer